To evaluate microperimetry changes in patients with acute macular edema secondary to branch retinal vein occlusion during a follow-up period of 12 months with intravitreal ranibizumab treatment (Lucentis; Novartis).
Patients with macular edema secondary to branch retinal vein occlusion received an intravitreous injection of 0.5 mg of ranibizumab (0.05 mL). Best-corrected visual acuity, Spectralis OCT (Heidelberg Engineering), and color fundus photography were performed at monthly intervals over a follow-up period of 1 year. Macular function was documented by microperimetry (Nidek, MP-1) at baseline, 3, and 12 months.
Data of 20 patients without lack of microperimetry results were included to the statistical analyses. The size of the area of absolute scotoma was reduced from 16% at baseline to 11.7% at Month 3 and remained stable in the entire study duration (P > 0.05). Mean differential light threshold improved significantly under therapy from 9.47 dB at baseline to 12.53 dB at 12 months (P < 0.001). Best-corrected visual acuity correlated significantly with central millimeter thickness and mean retinal sensitivity at baseline and at 12-month follow-up visits.
In addition to anatomical restoration and increased visual acuity, intravitreal ranibizumab also improved the central macular function in patients with acute macular edema after branch retinal vein occlusion.
In this prospective longitudinal study, patients with acute branch retinal vein occlusion presenting with clinically significant macular edema were treated with ranibizumab and were followed over 1 year. In addition to anatomical restoration and increase in visual acuity, a significant improvement in retinal sensitivity was observed. However, the change in absolute scotoma size was not statistically significant at Months 3 and 12 compared with baseline.
Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
Reprint requests: Stefan Sacu, MD, Department of Ophthalmology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria; e-mail: firstname.lastname@example.org
None of the authors has a proprietary interest in any of the products mentioned in this study.